GRI Bio, Inc. (GRI)
About GRI Bio, Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2021
- $0
- Net income
- -$12.0M
- Total assets
- $8.7M
- Market cap
- $3.5M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $12.0M
- Operating income
- -$12.0M
- Income tax
- $3.0K
- Net income
- -$12.0M
- EPS (basic)
- $-121.80
- EPS (diluted)
- $-121.80
Balance sheet
- Total assets
- $8.7M
- Current assets
- $8.6M
- Total liabilities
- $2.7M
- Current liabilities
- $2.6M
- Shareholders’ equity
- $6.0M
Cash flow
- Operating cash flow
- -$10.2M
- Investing cash flow
- -$3.0K
- Financing cash flow
- $13.4M
- Net cash flow
- $3.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $3.5M
- EPS (diluted)
- $-121.8
- Shares outstanding
- 2.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 24, 2023
GRI Bio, Inc. (GRI) Stock Price
- Reported a net loss of $12.0M in FY2021.
- Trading 98% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review GRI Bio, Inc..
Write a review
News about GRI Bio, Inc.
News & sentiment via Polygon.io
GRI Bio, Inc.: frequently asked questions
Is GRI Bio, Inc. an American company?
GRI Bio, Inc. is a US-based company headquartered in La Jolla, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is GRI Bio, Inc. headquartered?
GRI Bio, Inc. is headquartered in La Jolla, California, United States.
Is GRI Bio, Inc. publicly traded?
Yes — GRI Bio, Inc. is a publicly traded company. Its stock trades under the ticker symbol GRI on the NASDAQ.
What does GRI Bio, Inc. do?
GRI Bio, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
